Inclusion Criteria:

- Patients ≥18 years with advanced or metastatic solid tumor not amenable to any
clinical improvement by current standard treatments and suitable for a treatment with
cisplatin

- Life expectancy more than 3 months

- ECOG Performance status 0-1

- Absence of any conditions in which hypervolemia and its consequences (e.g.
increased stroke volume, elevated blood pressure) may represent a risk for the
patient

- Adequate baseline bone marrow, hepatic and renal function, defined as follows:

- Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L

- Bilirubin < 1.5 x ULN

- AST and/or ALT < 2.5 x ULN in absence of liver metastasis

- AST and/or ALT < 5 x ULN in presence of liver metastasis

- Serum creatinine < 1.5 x ULN

- Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50
ml/min

- Patients may have had prior therapy providing the following conditions are met:

- Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period
of 28 days

- Corticosteroid therapy wash out period of 14 days

- Surgery: wash-out period of 14 days

- Patients must give written informed consent to participate in the study

Exclusion Criteria:

- Previous signs of severe toxicity platinum related

- Patients must not receive any other investigational agents while on study

- New York Heart Association class III or IV cardiac disease

- Unstable angina

- Patients with myocardial infarction within the last six (6) months

- Patient with significant peripheral vascular disease

- Clinical signs of CNS involvement

- Patients with active or uncontrolled systemic disease/infections or with serious
illness or medical conditions, which is incompatible with the protocol

- Known hypersensitivity/allergic reaction to human albumin preparations or to any of
the excipients

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol

- Pregnancy or lactation. Patients - both males and females - with reproductive
potential (i.e. menopausal for less than 1-year and not surgically sterilized) must
practice effective contraceptive measures throughout the study. Women of childbearing
potential must provide a negative pregnancy test (serum or urine) within 14 days
prior to registration